Pfizer Will Not Launch EU Adalimumab

Despite Expected Imminent Approval For Amsparity Biosimilar To Humira

 
• By David Wallace
Bad weather
Pfizer cited ‘unfavorable conditions’ as the reason for its decision • Source: Shutterstock

More from Biosimilars

More from Products